Mitchell C A, Armstrong J G, Bartholomew M A, Scicchitano R
Eur J Respir Dis. 1983 Jul;64(5):340-6.
We assessed the bronchodilator response to cumulative doses of nebulised fenoterol in 16 patients with severe asthma to determine (1) the magnitude of the bronchodilator response, (2) the factors determining this response, and (3) the dose producing maximum bronchodilation. To reflect the degree to which ventilatory function returned to normal, individual bronchodilator responses were assessed as the change in FEV1 (post-fenoterol FEV1 - initial FEV1) and expressed as a percentage of the predicted maximum response (predicted FEV1 - initial FEV1). The bronchodilator response was extremely varied (about 55% of predicted maximum in six patients, 40% in three patients, and 20% in seven patients), as was the dose producing maximal bronchodilation (1 mg in three patients, 2 mg in six patients, and 2.5 or 3 mg in seven patients). In individual patients the maximum response could be predicted by the response to the initial dose of fenoterol and by the duration of the episode of severe asthma. The maximum response was not predicted by the initial severity of obstruction or the patient's usual treatment.
我们评估了16例重度哮喘患者对雾化吸入不同累积剂量非诺特罗的支气管舒张反应,以确定:(1)支气管舒张反应的程度;(2)决定该反应的因素;(3)产生最大支气管舒张作用的剂量。为反映通气功能恢复正常的程度,个体支气管舒张反应通过FEV1的变化(吸入非诺特罗后FEV1 - 初始FEV1)进行评估,并表示为预测最大反应(预测FEV1 - 初始FEV1)的百分比。支气管舒张反应差异极大(6例患者约为预测最大值的55%,3例患者为40%,7例患者为20%),产生最大支气管舒张作用的剂量也是如此(3例患者为1mg,6例患者为2mg,7例患者为2.5mg或3mg)。在个体患者中,最大反应可通过对初始剂量非诺特罗的反应以及重度哮喘发作的持续时间来预测。最大反应不能通过初始阻塞严重程度或患者的常规治疗来预测。